Gastroenterology
Volume 134, Issue 5 , Pages 1385-1395.e1 , May 2008

Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41

This study was presented at the American Association for the Study of Liver Disease meeting in Boston, October 29-November 2, 2004, and at the 40th Annual Meeting of the European Association for the Study of the Liver, in Paris, April 13-17, 2005.

  • Christoph S. Klade

      Affiliations

    • Intercell AG, Vienna, Austria
    • ,
  • Heiner Wedemeyer

      Affiliations

    • Medical School Hannover, Hannover, Germany
    • ,
  • Thomas Berg

      Affiliations

    • University Clinic Charité, Berlin, Germany
    • ,
  • Holger Hinrichsen

      Affiliations

    • University Clinic Schleswig-Holstein, Kiel, Germany
    • ,
  • Grazyna Cholewinska

      Affiliations

    • Wojewodzky Hospital Zakazny, Warshaw, Poland
    • ,
  • Stefan Zeuzem

      Affiliations

    • University Clinic, Homburg/Saar, Germany
    • ,
  • Hubert Blum

      Affiliations

    • Medical University Clinic, Freiburg, Germany
    • ,
  • Michael Buschle

      Affiliations

    • Intercell AG, Vienna, Austria
    • ,
  • Sandra Jelovcan

      Affiliations

    • Intercell AG, Vienna, Austria
    • ,
  • Vera Buerger

      Affiliations

    • Intercell AG, Vienna, Austria
    • ,
  • Erich Tauber

      Affiliations

    • Intercell AG, Vienna, Austria
    • ,
  • Juergen Frisch

      Affiliations

    • Intercell AG, Vienna, Austria
    • ,
  • Michael P. Manns

      Affiliations

    • Medical School Hannover, Hannover, Germany
    • Corresponding Author InformationAddress requests for reprints to: Michael P. Manns, MD, Prof, Medizinische Hochschule Hannover, Abt. Gastroenterologie, Hepatologie und Endokrinologie, Carl-Neuberg Str. 1, 30625 Hannover, Germany. fax: (49) 511 532 4896.

Received 28 September 2006 ,Accepted 24 January 2008.

References 

  1. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–1359
  2. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292
  3. Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine. 2006;24:4343–4353
  4. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215–229
  5. Lechner F, Wong DKH, Dunbar PR, et al. Analysis of successful immune responses in persons infected with Hepatitis C virus. J Exp Med. 2000;191:1499–1512
  6. Cox AL, Mosbruger T, Lauer GM, et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42:104–112
  7. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6:578–582
  8. Lauer GM, Ouchi K, Chung RT, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol. 2002;76:6104–6113
  9. Day CL, Lauer GM, Robbins GK, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002;76:12584–12595
  10. Wertheimer AM, Miner C, Lewinsohn DM, et al. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology. 2003;37:577–589
  11. Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004;127:924–936
  12. Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol. 2001;75:5550–5558
  13. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002;169:3447–3458
  14. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med. 2005;201:1709–1714
  15. Kanto T, Hayashi N, Takehara T, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol. 1999;162:5584–5591
  16. Bain C, Fatmi A, Zoulim F, et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology. 2001;120:512–524
  17. Ciesek S, Liermann H, Cornberg M, et al. Impaired TRAIL-dependent cytotoxic activity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepat. 2008;15:200–211
  18. Sugimoto K, Ikeda F, Stadanlick J, et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003;38:1437–1448
  19. Cabrera R, Tu Z, Xu Y, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2004;40:1062–1071
  20. Rushbrook SM, Ward SM, Unitt E, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol. 2005;79:7852–7859
  21. Boettler T, Spangenberg HC, Neumann-Haefelin C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol. 2005;79:7860–7867
  22. Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology. 2002;36:743–754
  23. Lauer GM, Lucas M, Timm J, et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol. 2005;79:12979–12988
  24. Wiegand J, Cornberg M, Aslan N, et al. Fate and function of peripheral HCV-specific T-cells during peginterferon α-2b therapy of acute hepatitis C. Antivir Ther. 2007;12:303–316
  25. Gjertson DW, Terasaki PL. HLA 1998. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics; 1998;
  26. Ward S, Lauer G, Isba R, et al. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol. 2002;128:195–203
  27. Buschle M, Schmidt W, Zauner W, et al. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc Natl Acad Sci U S A. 1997;94:3256–3261
  28. Schmidt W, Buschle M, Zauner W, et al. Cell-free tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci U S A. 1997;94:3262–3267
  29. Mattner F, Fleitmann JK, Lingnau K, et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res. 2002;62:1477–1480
  30. Luhrs P, Schmidt W, Kutil R, et al. Induction of specific immune responses by polycation-based vaccines. J Immunol. 2002;169:5217–5226
  31. Lingnau K, Egyed A, Schellack C, et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine. 2002;20:3498–3508
  32. Schlaphoff V, Klade CS, Jilma B, et al. and the IC41 Study Group Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine. 2007;25:6793–6806
  33. Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology. 2003;38:1289–1296
  34. Neumann-Haeflin C, Killinger T, Timm J, et al. Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site. J Gen Virol. 2007;88:1986–1991
  35. Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40:87–97

 Conflicts of interest: C.S.K. is an employee of Intercell AG. H.W., M.P.M., H.B., H.H., T.B., and S.Z. have received consultancy fees from Intercell AG.

 C.K.L. and H.W. contributed equally to this work.

 Supported by research grants from Intercell AG (to H.W., T.B., H.H., G.C., S.Z., and H.B.) and by a generous grant from the Austrian Fond zur Förderung der Forschung (FFG).

PII: S0016-5085(08)00346-6

doi: 10.1053/j.gastro.2008.02.058

Gastroenterology
Volume 134, Issue 5 , Pages 1385-1395.e1 , May 2008

Article Tools

* Image Usage & Resolution